The primary efficacy outcome occurred in 36 of 134 patients ( 27 % ) who received the 200-mg dose of FXI-ASO and in 3 of 71 patients ( 4 % ) who received the 300-mg dose of FXI-ASO , as compared with 21 of 69 patients ( 30 % ) who received enoxaparin .